ARBUTUS BIOPHARMA CORP (ABUS)
Health Care · Antiviral therapeutics / Hepatitis B treatments · NASDAQ
Hepatitis B-focused biotech leveraging RNAi technology and patent litigation settlements to fund clinical programs targeting chronic HBV infection.
What ARBUTUS BIOPHARMA CORP does
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B infection, a liver disease caused by the hepatitis B virus. The company is advancing imdusiran and AB-101 as product candidates aimed at preventing complications of hepatitis B disease progression, decreasing viral burden, and providing more efficacious finite treatments than current standard of care. Arbutus has also generated significant revenue from patent infringement settlements with Moderna and ongoing litigation against Pfizer/BioNTech and the U.S. government.
Themes: ["hepatitis B / cHBV treatment","RNA interference / RNAi therapeutics","patent licensing and IP litigation","clinical development"]
Fundamentals
- Price$5.14 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+53.9% as of 2026-07-09 close
- P/E6.33 as of 2026-07-10
- Net margin+84.0% as of 2026-07-10
- ROE+129.3% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Revenue growth (YoY)+2889.9% as of 2026-07-10
- Revenue CAGR (3y)-28.8% SEC XBRL
- Beta0.59 as of 2026-07-10
Key risks (from latest filing)
["Patent infringement litigation outcomes and timing with Pfizer/BioNTech and the U.S. government are uncertain and could materially impact future revenue and financial position","Clinical development of imdusiran and AB-101 may not achieve desired outcomes or obtain necessary regulatory approvals, delaying or preventing commercialization","Company dependence on cash from litigation settlements to fund operations; significant net cash burn and uncertainty regarding runway and need for additional financing"]
Competitors & peers
- Gilead Sciences (GILD)
- Roche/Genentech
- GlaxoSmithKline (GSK)
- Merck (MRK)
- Vir Biotechnology (VIR)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.